Systematic review of levodopa dose equivalency reporting in Parkinson's disease.
Claire L Tomlinson, Rebecca Stowe, Smitaa Patel...
https://pubmed.ncbi.nlm.nih.gov/21069833Actively Recruiting
All Genders
Healthy Volunteers
ID03872102
Quantitative Diagnostics of Parkinsonian Syndromes Using Multi-modal Neuroimaging and Deep Learning
Led by University of Texas Southwestern Medical Center · Updated on 2026-01-27
90
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying Parkinson disease (PD), multiple systems atrophy (MSA), progressive supranuclear palsy (PSP), and healthy controls to find biomarkers using neuroimaging that can predict how fast PD progresses and help distinguish between these conditions. The study aims to fill gaps in managing parkinsonian symptoms by developing imaging biomarkers for disease progression and differential diagnosis. This observational study lasts two years and uses advanced imaging and statistical methods to analyze brain scans and clinical data. The study has two parts: first, enrolling PD patients with known progression rates to identify imaging markers related to disease speed; second, recruiting new participants with PD, MSA, PSP, and healthy controls to undergo clinical assessments and neuroimaging at three visits about 6-8 months apart. Evaluations include various disease-specific rating scales and questionnaires. These data will be analyzed with machine learning to develop biomarkers for diagnosis and progression. Participants will attend study visits where they undergo multimodal neuroimaging and clinical tests to track disease symptoms and severity. Clinical scales used include the MDS-UPDRS for PD, UMSARS for MSA, PSPRS for PSP, and others, repeated at baseline, mid-study, and end of study visits. The research team will measure changes over time and correlate imaging findings with clinical progression. The study includes healthy volunteers for comparison and requires participants to commit to the full two-year period with no plans to move away.
CONDITIONS
Brief Title
Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging
Who Can Participate
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Diagnosis of Parkinson disease with sufficient clinical data to determine progression rate for Aim 1
- Availability of a matched participant in the opposite progression group for Aim 1
- Willingness to participate in imaging and provide written informed consent
- PD subjects with diagnosis duration less than 5 years for Aim 2
- MSA subjects with diagnosis duration less than 5 years for Aim 2
- PSP subjects meeting probable PSP criteria for Aim 2
- Control subjects matched by age and sex with no neurodegenerative history
- Ability and willingness to participate in imaging and clinical visits for 2 years
- Agreement by subject and investigator that participant can complete the 2-year study period
You will not qualify if you...
- Contraindications to multimodal neuroimaging
- Females of child-bearing potential aged 18-55 unless confirmed not pregnant
- Non-English speakers
- Right-handed finger amputees or right hand cast at enrollment
- Clinically significant liver, kidney, lung, metabolic, hormone disturbances posing safety risk
- Significant heart disease posing safety risk
- Infectious disease or medical comorbidity posing safety risk
- Severe drug allergy or hypersensitivity history
- Drug, alcohol, or substance dependence or abuse within last year
- Current chemotherapy or radiation for cancer
- Recreational drug use in past six months
- Central nervous system disease or brain injury precluding participation
- Psychiatric or neurological disorder precluding participation
- Inability to keep research appointments
- Severe disease progression preventing imaging participation for Aim 1
- Lack of suitable matched participant for Aim 1
- PD subjects with specific neurological signs or conditions as listed
- MSA subjects with neuropathy, hallucinations, late onset, family history, or lesions
- PSP subjects with memory impairment, autonomic failure, hallucinations, motor neuron signs, sudden symptom onset, encephalitis, ataxia, or postural instability
- Control subjects deemed unsuitable by investigator for control role
- All exclusions apply to both study aims unless otherwise noted
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Baseline visit
Participants undergo several types of neuroimaging and clinical assessments to evaluate disease severity and enable differential diagnosis between Parkinson disease, multiple systems atrophy, progressive supranuclear palsy, and healthy controls.
1 visit (in-person)
Long-term Monitoring
Duration - Approximately 2 years
Participants are followed clinically over 2 years with repeated neuroimaging and clinical assessments to track disease progression and evaluate biomarkers.
3 visits approximately 6-8 months apart
Trial Site Locations
Total: 1 location
1
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Actively Recruiting
Loading map...
Research Team
P
Padraig E O'Suilleabhain, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here